Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women

Advances in Medical Sciences

Volumn 57, Issue 1, 2012, Pages 51-57

  Papierska, L ^a   Rabijewski, M ^a   Kasperlik Zaluska A ^a   Zgliczynski W ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Dehydroepiandrosterone; Glucocorticoid induced osteoporosis

Indexed keywords

ANDROSTENEDIONE; CALCIUM CARBONATE; COLECALCIFEROL; ESTRADIOL; FOLLITROPIN; HYDROCHLOROTHIAZIDE; OSTEOCALCIN; PRASTERONE; PREDNISONE; SOMATOMEDIN C; TESTOSTERONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET SUPPLEMENTATION; FEMALE; FEMUR NECK; HORMONE BLOOD LEVEL; HUMAN; LUMBAR SPINE; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SUBSTITUTION THERAPY;

EID: 84865169416     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-011-0060-9     Document Type: Article

References (39)

1. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991 Feb;72(2):382-6.
2. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39.
3. Manelli F, Carpinteri R, Bossoni S, Burattin A, Bonadonna S, Agabiti Rosei E, Giustina A. Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res. 2002;30:174-83.
4. Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol. 2007 Apr;38(4):467-79.
5. Fujikawa H, Okura F, Kuwano Y, Sekizawa A, Chiba H, Shimodaira K, Saito H, Yanaihara T. Steroid sulfatase activity in osteoblast cells. Biochem Biophys Res Commun. 1997 Feb 3;231(1):42-7.
6. Bodine PV, Riggs BL, Spelsberg TC. Regulation of c-fos expression and TGF-beta production by gonadal and adrenal androgens in normal human osteoblastic cells. J Steroid Biochem Mol Biol. 1995 Feb;52(2):149-58.
7. Purohit A, Flanagan AM, Reed MJ. Estrogen synthesis by osteoblast cell lines. Endocrinology. 1992 Oct;131(4):2027-9.
8. Nawata H, Tanaka S, Tanaka S, Takayanagi R, Sakai Y, Yanase T, Ikuyama S, Haji M. Aromatase in bone cell: Association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):165-74.
9. Szathmári M, Szũcs J, Fehér T, Holló I. Dehydroepiandrosterone sulphate and bone mineral density. Osteoporos Int. 1994 Mar;4(2):84-8.
10. Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997 Jul- Aug;15(4):387-92.
11. Sambrook P, Birmingham J, Champion D, Kelly P, Kempler S, Freund J, Eisman J. Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. J Rheumatol. 1992 Mar;19(3):357-61.
12. Turner RT, Lifrak ET, Beckner M, Wakley GK, Hannon KS, Parker LN. Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol. 1990 Apr;258(4 Pt 1):E673-7.
13. Devogelaer JP, Crabbé J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed). 1987 Mar 28;294(6575):798-800.
14. Papierska L, Kasperlik-Zaluska A, Stopinska- Gluszak U, Misiorowski W, Migdalska B, Snochowska H. Wplyw leczenia preparatem "Gynodian" na gȩstość mineralna̧ kości u pacjentek z niewydolnościa̧ kory nadnerczy [Effect of Gynodian injections on bone mineral density in female patients with Addison's disease]. Endokrynol Pol. 2000;51:297-303. Polish.
15. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: A randomized, controlled trial. J Clin Endocrinol Metab. 2008 Feb;93(2):400-9.
16. Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996 Sep;150 Suppl:S43-50.
17. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J (Engl). 2002 Mar;115(3):402-4.
18. Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab. 2002 Apr;87(4):1544-9.
19. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: A randomized, controlled trial. J Clin Endocrinol Metab. 2006 Aug;91(8):2986-93.
20. Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab. 2008 Dec;93(12):4767-73.
21. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998 Feb;25(2):285-9.
22. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ.UK Consensus Group on management of glucocorticoidinduced osteoporosis: An update. J Intern Med. 1998 Oct;244(4):271-92.
23. Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, Chatellier G, Azizi M, Faucounau V, Porchet H, Forette F, Baulieu EE. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000 Sep;85(9):3208-17.
24. Arlt W, Haas J, Callies F, Reincke M, Hübler D, Oettel M, Ernst M, Schulte HM, Allolio B. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab. 1999 Jun;84(6):2170-6.
25. Arlt W, Justl HG, Callies F, Reincke M, Hübler D, Oettel M, Ernst M, Schulte HM, Allolio B. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab. 1998 Jun;83(6):1928-34.
26. Bruder JM, Sobek L, Oettel M. Dehydroepiandrosterone stimulates the estrogen response element. J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):461-6.
27. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76.
28. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002 Sep;110(6):771-81.
29. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster JE. Postmenopausal dehydroepiandrosterone administration increases free insulinlike growth factor-I and decreases high-density lipoprotein: A six-month trial. Fertil Steril. 1998 Jul;70(1):107-10.
30. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf). 2000 Nov;53(5):561-8.
31. Johannsson G, Burman P, Wirén L, Engström BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: A placebo-controlled trial. J Clin Endocrinol Metab. 2002 May;87(5):2046-52.
32. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999 Sep 30;341(14):1013-20.
33. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol. 2001 Oct;15(10):1781-9.
34. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.
35. Clemmons DR. Role of insulin-like growth factor-1 in reversing catabolism. J Clin Endocrinol Metab. 1992 Nov;75(5):1183-5.
36. Delany AM, Pereira RM, Pereira RC, Canalis E. The cellular and molecular basis of glucocorticoid actions in bone. Front Horm Res. 2002;30:2-12.
37. Bruyere O, Stephaniak N, Reginster JY. Biochemical markers in glucocorticoid-induced osteoporosis. Front Horm Res. 2002;30:49-59.
38. Bouvard B, Legrand E, Audran M, Chappard D. Glucocorticoid-Induced Osteoporosis: A Review. Clinic Rev Bone Miner Metab. 2010;8:15-26.
39. Robinzon B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford). 1999 Jun;38(6):488-95.